PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1513444
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1513444
US Preimplantation Genetic Diagnosis Market is valued at approximately USD 23.62 million in 2023 and is anticipated to grow with a healthy growth rate of more than 11.40% over the forecast period 2024-2032. Preimplantation Genetic Diagnosis (PGD) is a sophisticated reproductive technology used with In Vitro Fertilization (IVF) to screen embryos for genetic conditions before implantation. This technique enhances the likelihood of a healthy baby for couples at risk of passing on genetic conditions. IVF involves hormone stimulation of the ovaries, egg retrieval, and fertilization in a lab. Embryos are cultured to the blastocyst stage, where cells are biopsied and assessed for genetic defects. Only healthy embryos are selected for uterine transfer, reducing the transmission of genetic disorders and improving IVF success rates. PGD raises ethical concerns about embryo selection and genetic confidentiality but is beneficial for couples with a family history of genetic issues, multiple miscarriages, or infertility due to genetic abnormalities. The US Preimplantation Genetic Diagnosis Market is growing due to advancements in genetic technologies, increasing awareness of genetic disorders, and the trend of delayed parenthood. Rising infertility rates and expanding applications of PGD for non-medical purposes further drive market growth.
The US Preimplantation Genetic Diagnosis (PGD) market is driven by the increasing prevalence of genetic disorders, prompting more couples to opt for PGD to avoid passing on hereditary conditions to their children. PGD's ability to provide genetic information about embryos before implantation is a crucial factor driving its adoption among couples undergoing fertility treatments, as it enhances the chances of a successful pregnancy. The rises trend of delayed parenthood, coupled with increasing awareness about fertility preservation, is expected to drive the demand for PGD services in the US market. However, the market faces certain restraints. The high cost associated with PGD procedures is a barrier for many couples seeking these services. Ethical and legal concerns surrounding the use of PGD, particularly regarding embryo selection for non-medical reasons, pose challenges to market growth. Furthermore, the lack of insurance coverage for PGD procedures in some cases limits its accessibility to a broader population.